This review integrates current evidence on how brain peptides contribute to AD pathophysiology, summarizes recent progress in peptide-based therapeutic strategies and delivery platforms, and critically examines the remaining barriers to clinical translation, including bloodbrain barrier penetration, metabolic stability, off-target effects, and the need for biomarker-guided patient stratification
Tom Carper (D-DE), and Delaware Secretary of Agriculture Don Clifton, who delivered opening remarks highlighting Delawares agricultural industry, its contributions to the local economy and the importance of empowering local students to play a role in advancing the industry
Typically, such compositions are prepared either as liquid solutions or suspensions, however solid forms such as tablets, pills, powders and the like are also contemplated
Sep 23 2014
Human clinical trial evidence (strongest) Cerebrolysin in glaucoma: Multiple small trials (20-60 patients each) showing slowed visual field loss and preserved optic nerve structure over 6-12 months